325 related articles for article (PubMed ID: 27939836)
1. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
2. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
6. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
[TBL] [Abstract][Full Text] [Related]
7. Triptorelin in the management of prostate cancer.
Ploussard G; Mongiat-Artus P
Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
[TBL] [Abstract][Full Text] [Related]
8. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
10. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
Novara G; Galfano A; Secco S; Ficarra V; Artibani W
Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
[TBL] [Abstract][Full Text] [Related]
11. [Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer].
Botto H; Rouprêt M; Mathieu F; Richard F
Prog Urol; 2007 Apr; 17(2):235-9. PubMed ID: 17489325
[TBL] [Abstract][Full Text] [Related]
12. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
13. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.
Morote J; Comas I; Ferrer R; Planas J; Celma A; Regis L
J Biomed Sci; 2017 Oct; 24(1):81. PubMed ID: 29058606
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
16. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Oefelein MG; Cornum R
J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
[TBL] [Abstract][Full Text] [Related]
17. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
Bolton EM; Lynch T
BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
[TBL] [Abstract][Full Text] [Related]
18. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Guess B; Scholz M
J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
[No Abstract] [Full Text] [Related]
19. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
Kuhn JM; Abourachid H; Brucher P; Doutres JC; Fretin J; Jaupitre A; Jorest R; Lambert D; Petit J; Pin J; Blumberg J; Dufour-Esquerré F
Eur Urol; 1997; 32(4):397-403. PubMed ID: 9412795
[TBL] [Abstract][Full Text] [Related]
20. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]